A framework for cost-effectiveness analysis from clinical trial data

Health Economics

Volumn 10, Issue 4, 2001, Pages 303-315

  O'Hagan, Anthony ^a   Stevens, John W ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Bayesian analysis; Cost effectiveness acceptability curve; Log normal distribution; Net benefit; Normal distribution; Outcomes

Indexed keywords

ARTICLE; ASTHMA; BAYES THEOREM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; HUMAN; MATHEMATICAL MODEL; METERED DOSE INHALER; METHODOLOGY; PRIORITY JOURNAL; STATISTICAL PARAMETERS; TREATMENT OUTCOME;

BAYES THEOREM; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; GREAT BRITAIN; HUMANS; MODELS, ECONOMETRIC; RANDOMIZED CONTROLLED TRIALS; STATE MEDICINE;

EID: 0034950339     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.617     Document Type: Article

References (21)

1. Costs, effects and C/E ratios alongside a clinical trial
2. Confidence intervals for cost/effectiveness ratios
3. Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem
4. Statistical inference for cost-effectiveness ratios
5. A note on confidence intervals in cost-effectiveness analysis
6. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis
7. Bayesian estimation of cost-effectiveness ratios from clinical trials
8. Inference for the C/E acceptability curve and C/E ratio
9. Bayesian cost effectiveness analysis from clinical trial data
10. A Bayesian approach to the economic evaluation of health care technologies
11. A Bayesian approach to stochastic cost-effectiveness analysis
12. A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US
13. Cost-effectiveness analyses of salmeterol/fluticasone propionate combination product and fluticasone propionate in patients with asthma. II: Study methodologies
14. Cost effectiveness of helicobacter pylori eradication therapies in patients with duodenal ulcer, an analysis of tripletherapy versus two dual therapy alternatives
15. Cost effectiveness analysis of improved blood pressure control with type 2 diabetes: UKPDS 40
16. Low doses versus high doses of the angiotensin converting enzyme inhibitor lisinopril in chronic heart failure: A cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril And Survival (ATLAS) study
17. The irrelevance of inference: A decision-making approach to the stochastic evaluation of health care technologies
18. A one-year comparison of Turbuhaler® versus pressurized metered-dose inhaler (pMDI) in asthmatic patients
19. Bootstrap confidence intervals for cost-effectiveness ratios: Some simulation results
20. Cost-effectiveness analysis of a dry-powder inhaler (Turbuhaler® versus a pressurized metered dose inhaler in patients with asthma